



Viracor



ImmuKnow®

Immune Cell Function Assay

Assessing Global Immune Function Over Time Puts You in the KNOW

KNOW HOW TO USE RESULTS. KNOW HOW TO TREAT.

By identifying changes in CD4 cell ATP production^{1,2}, the ImmuKnow® assay helps define a range of stable immune function for solid organ transplant patients (SOT).

Results that lie outside an individual patient's range may help indicate an increased risk of infection or rejection and aid in the diagnosis and differentiation of SOT complications.

ImmuKnow® is the only FDA-cleared, reimbursable assay designed to detect changes in immune cell function, giving you crucial insight for individualized transplant patient management.

LEARN MORE ABOUT IMMUKNOW:

www.eurofins-viracor.com/our-testing/immuknow/



View Our Test Menu ►



Know the Facts on ImmuKnow®

ImmuKnow's clinical utility has been well characterized and validated:

- Over 400,000 assays run
- 25 prospective and interventional studies in 1000+ transplant recipients
- More than 120 clinical studies

Global immune status monitoring has been used to:

- Identify kidney,⁴ liver,³ lung,^{5,6} and heart⁷ transplant patients with low immune response, which has the potential to lead to infection
- Define immunologic stability in various solid organ transplant patients^{7,8}
- Longitudinally assess changes in transplant patients' immune status, giving clinicians an additional tool in treatment optimization decisions^{3,7-9}


FREQUENCY OF TESTING

- Pre-transplant
- Clinic visits at approximately:
 - < Day 1
 - < Weeks 1-4, 6, 8
 - < Months 3-6, 9, 12

Testing was repeated within one week of suspected or confirmed adverse event and one week after event resolution.

RISK ANALYSIS CURVE

Values previously documented as thresholds for risks of infection and rejection were utilized in the study design.²



“ In conclusion, the present prospective, interventional, controlled and randomized study demonstrates that ImmuKnow® provides a useful biomarker which enables optimizing immunosuppression to improve patient outcomes by preventing bacterial and fungal infections, reducing immunosuppressant drug use and improving 1-year patient survival post liver transplantation.^{10”}

Get Fast Accurate Results

Find out more at eurofins-viracor.com
or contact us at info@eurofins-viracor.com
or call **800-305-5198**



About Viracor

With over 40 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is passionate about delivering accurate, timely and actionable results, never losing sight of the connection between the testing it performs and the patients it serves.

Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit eurofins.com and eurofins-viracor.com

References

1. Augustine NH, Pasi BM, Hill HR. Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. J Clin Lab Anal. 2007;21:265-270.
2. Sottong PR, Rosebrock JA, Britz JA, Kramer TR. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol. 2000;7:307-311.
3. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 2009;15:216-222.
4. Sánchez-Velasco P, Rodrigo E, Valero R, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22:55-60.
5. Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant. 2008;27:990-994.
6. Hussain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation. 2009;87:1852-1857.
7. Kiyosaki K, Kobashigawa J, Patel J, et al. The benefit of immune monitoring (Cylex): a review of 864 immune monitoring assays in heart transplantation. Presented at: The International Society for Heart and Lung Transplantation 29th Annual Meeting and Scientific Sessions; April 22-25, 2009; Paris, France; Abstract 511.
8. Knight RJ, Kerman RH, McKissick E, et al. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Clin Transplant. 2008;22:645-650.
9. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.
10. Ravaioli M, Neri F, et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. Transplantation. Epub 2015 March 9.
11. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.